On Friday, Royal Bank of Canada (NYSE:RY)’s shares inclined 1.63% to $60.36.
Royal Bank of Canada (RY) notes that affordability for single-detached homes and condos in Manitoba evolved in opposite directions during the first quarter.
RBC says that current housing affordability conditions in the province likely do not pose unusual challenges for home buyers as affordability measures remain remarkably close to long-term averages.
The RBC Housing Affordability measures, which capture the province’s proportion of pre-tax household income needed to service the costs of owning a home at market values, were mixed in the first quarter of 2015 (a decrease in the measure represents an improvement in affordability). RBC’s measures for both bungalows and two-storey homes rose by 0.3 percentage points to 35.6 per cent and 36.9 per cent, respectively. The measure for condos fell noticeably by 1.1 percentage points to 22.2 per cent.
During Q1 2015, affordability measures at the national level edged lower by 0.3 percentage points to 27.1 per cent for condominiums and 0.2 percentage points to 47.9 per cent for two-storey homes. The measure for detached bungalows was unchanged at 42.7 per cent.
RBC’s housing affordability measure for the benchmark detached bungalow in Canada’s largest cities in Q1 2015 is as follows: Vancouver 85.6 (up 2.8 percentage points from Q4 2014); Toronto 57.3 (up 0.6 percentage points); Montreal 37.2 (down 0.2 percentage points); Ottawa 35.4 (down 0.6 percentage points); Calgary 32.8 (down 1.0 percentage points); Edmonton 32.8 (down 0.8 percentage points).
Royal Bank of Canada, together with its auxiliaries, operates as a diversified financial service company worldwide. The company operates through five segments: Personal & Commercial Banking, Wealth Administration, Insurance, Investor & Treasury Services, and Capital Markets. The Personal & Commercial Banking segment engages in the personal and business banking operations, auto financing, and retail investment businesses, in addition to cards and payment solutions business. \
Time Warner Cable Inc (NYSE:TWC)’s shares gained 1.19% to $183.50.
Time Warner Cable is offering its customers a no fuss option for entertaining children indoors this summer with a month-long category featuring 35 animated films accessible on Movies On Demand. The category, titled “Animated Heroes”, features popular animated movies counting: Despicable Me; Toy Story; Cars; The Incredibles; and Wreck-It Ralph. Customers can access the category by tuning to the Movies On Demand channel, clicking on “Enjoy Better” and selecting “Animated Heroes.”
Time Warner Cable Inc., together with its auxiliaries, provides video, high-speed data, and voice services in the United States. It operates in three segments: Residential Services, Business Services, and Other Operations. The Residential Services segment offers video services, counting video on demand, digital video recorder, and start over and look back services; high-speed data services that comprise communication tools and personalized services, such as email, PC security, parental controls, and online radio services; voice services that comprise unlimited calling in the United States, Canada, Puerto Rico, and Mexico; and IntelligentHome, a security and home administration service.
At the end of Friday’s trade, RXi Pharmaceuticals Corp (NASDAQ:RXII)‘s shares surged 9.50% to $0.528.
RXi Pharmaceuticals Corp (RXII) declared that it received two Notices of Allowance from the United States Patent and Trademark Office (USPTO). One is on RXi’s novel, self-delivering RNAi platform (sd‑rxRNA®). The patent, titled “Reduced Size Self-Delivering RNAi Compounds,” covers both the composition and methods of use of RXi’s self-delivering platform. The patent, once issued, will be planned to expire in 2031.
In addition, RXi declared that it has also received a Notice of Allowance from the USPTO covering the composition and methods of use for rxRNAori® compounds targeting Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). These compounds may be beneficial for the treatment of inflammatory diseases and/or metabolic diseases. RXi’s rxRNAori platform are highly potent RNAi compounds which require delivery vehicles to be taken up by cells and tissues of interest. The patent, once issued, will be planned to expire in 2029.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs comprise RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, in addition to for the administration of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma.
Cardinal Health Inc (NYSE:CAH), ended its Friday’s trading session with 1.57% gain, and closed at $85.48.
Cardinal Health Inc (CAH) declared the completion of the acquisition of The Harvard Drug Group (THDG). A distributor of generic pharmaceuticals, over-the-counter medications and related products to retail, institutional and alternate care customers, THDG was owned by Court Square Capital Partners. The $1.115 billion acquisition was an all-cash transaction using existing cash and new debt.
Headquartered in Livonia, Mich., The Harvard Drug Group had revenues of about $450 million in 2014. There are 450 employees and two distribution facilities comprised of in the transaction.
In addition to enhancing the company’s generic pharmaceutical distribution business, the acquisition expands Cardinal Health’s existing telesales programs and capabilities; broadens the company’s portfolio of over-the counter pharmaceutical products; and brings specialized packaging offerings to meet the needs of hospital systems and other institutions.
Cardinal Health, Inc., a healthcare services company, provides pharmaceutical and medical products and services in the United States and internationally. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, over-the-counter healthcare, specialty pharmaceutical, and consumer products to retailers, including chain and independent drug stores and pharmacy departments of supermarkets and mass merchandisers; hospitals; and other healthcare providers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
